Please assess the completion status of the following clinical trial:

Trial Title: Corticosteroid Dosage for Crohn's Disease Flare

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Established diagnosis of Crohn's disease~* Diagnosis of Crohn's flare~* Decision by treating gastroenterologist to start corticosteroid therapy~Exclusion Criteria:~* Patients in whom corticosteroid therapy is contraindicated: immunocompromised (active cancer on chemotherapy or radiation treatment), severe liver disease (decompensated cirrhosis, active alcoholic hepatitis), end-stage renal disease on dialysis, AIDS or AIDS-defining illness; myocardial infarction within the past year; NYHA Class 4 heart failure~* Patients on systemic corticosteroid therapy currently or within the past 8 weeks~* Patients not on stable doses of immunomodulators or biologics for at least 8 weeks~* Infectious colitis (e.g., C. difficile, CMV, HSV)~* Systemic infections (bacteremia, fungal infections)~* Fulminant Crohn's disease~* Patients who require imminent surgery~* Abscess~* Pregnancy~* Weight \<35 kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Weight-based (Type: ACTIVE_COMPARATOR): Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
- Fixed dose (Type: ACTIVE_COMPARATOR): Corticosteroid dose fixed at equivalent to 40mg prednisone daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).